VPVaibhavi Peshattiwar

Vaibhavi Peshattiwar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vaibhavi Peshattiwar has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Squalamine prevents motor and non-motor symptoms in the paraquat and lectin rat model of the body-first subtype of Parkinson's disease

    by Caroline C Swain, Vaibhavi V Peshattiwar, Dipesh Pokharel, Khoi Le, Isabel Kennedy, Julia Kalbus, Denise Barbut, Michael Zasloff, Thyagarajan Subramanian, Kala Venkiteswaran

    Increasing evidence supports the existence of a distinct body-first subtype of Parkinson's disease (PD), in which the initial site of pathology is in the gut. Animal models that recapitulate the body-first subtype of PD are needed. We tested the hypothesis that non-motor features of the body-first subtype of PD are recapitulated in the paraquat and lectin (P + L) rat model of PD, a model that has previously demonstrated the pathological motor progression of this subtype of PD. Then, we tested whether oral squalamine, a gastrointestinal prokinetic that has been shown to reduce formation of pathological α-synuclein, could prevent pathology, motor, and non-motor findings. Rats (n = 93) were orally gavaged for seven days with paraquat (1 mg/kg) and lectin (0.05%) in 1% sucrose solution. A subset of rats (n = 37) were given 30 days of squalamine (20 mg/kg) in their drinking water immediately following P + L treatment. Rats were tested for parkinsonian motor deficits, gastrointestinal dysmotility, sleep abnormalities, and cognitive deficits. Rats were euthanized and their brains processed for phospho-S 129 -α-synuclein pathology and neurodegeneration. We show that the P + L rat model recapitulates non-motor features and pathology of gastrointestinal dysmotility and sleep abnormalities seen in the body-first subtype of PD. We show that oral squalamine prevents motor deficits, gastrointestinal dysmotility, and sleep abnormalities, and diminishes phospho-S 129 -α-synuclein pathology and neurodegeneration in the nigrostriatal pathway. We show that the P + L rat model recapitulates many features of the body-first subtype of PD and provides pre-clinical evidence for the use of squalamine to mitigate progression in the body-first subtype of PD.

  • Open Access

    A novel rat model of body first subtype of Parkinson’s disease

    by Vaibhavi Peshattiwar, Caroline Swain, Dipesh Pokharel, Khoi Le, Isabel Kennedy, Kala Venkiteswaran, Thyagarajan Subramanian

    The recent growing evidence support the existence of two subtypes of Parkinson’s disease (PD), a body first and brain first subtype owing to variability in the disease site of onset as well as disease progression. Animal models which could replicate the specific differences of these subtypes are important to explore the pathophysiology as well as to evaluate novel treatment options. Here, we describe an animal model of body first PD subtype developed using repeated low dose exposure of environmental neurotoxin Paraquat (P) and Lectin (L) to characterize its PD-like manifestations. We administered P+L (P+L, p.o.) daily to rats for 90 days. These animals underwent motor and non-motor behavioral tests at various time intervals. After 21 weeks, post-mortem histopathological analysis was performed to assess neurodegeneration. Onset of motor deficits initiated unilaterally from week 4 of P+L followed by gradual progression towards bilateral symptoms that were levodopa responsive. This model also replicates non motor features including cognitive deficits in tests like Novel Object Recognition Test and Y maze as well as sleep abnormalities. The histopathology showed nigrostriatal dopaminergic degeneration and proteinase K resistant S129 alpha-synucleinopathy both in the gut and the brain. The replication of both progressive motor and non-motor features in this rat model corroborates body first subtype of PD therefore making it an attractive option for testing neuroprotective experimental therapeutics and avenue to understand pathophysiological mechanisms.

  • Open Access

    Exploring the therapeutic utility of apocynin in multifactorial neurodegenerative Alzheimer’s disease in a preclinical animal model

    by Sneha Bagle, Suraj Muke, Vaibhavi Peshattiwar, Aakruti Kaikini, Vikas Dighe, Sadhana Sathaye

    Aim: Alzheimer’s disease (AD) devastates learning and memory, the defining faculties of the human species. Extracellular amyloid beta (Aβ) deposits and intracellular hyperphosphorylated tau are hallmarks of AD pathology. The exact cause of the disease remains unknown, but a lot of data support AD to be a multifactorial disease. Given the central roles of oxidative stress and neuroinflammation in AD pathogenesis, apocynin, a potent antioxidant and anti-inflammatory agent, was selected for investigation. Apocynin is an aromatic ketone, a naturally occurring methoxy-substituted catechol known to possess numerous biological activities, namely anti-oxidant, anti-inflammatory, etc. The present study assessed apocynin’s potential against an Aβ1–42-induced sporadic AD rat model. Methods: In the present study, Wistar rats were subjected to intrahippocampal administration of 200 µmol/L of Aβ1–42 peptide in right hemisphere. Further were treated with apocynin 50, 150, and 300 mg/kg per orally for 28 days. The study examined the neurobehavioral aspects using the Barnes Maze test (BMT). Hippocampus was examined for the antioxidant (SOD, GSH, catalase, and LPO), inflammatory (TNF-α) parameters, RAGE, caspase-3, PGC-1α expression, and IHC analysis for Aβ load, adult hippocampal neurogenesis markers (BDNF, Ki67, DCX, NeuN), at the end of 28 days. Results: Apocynin administration demonstrated significant improvement in cognitive functions, diminished oxidative stress and inflammatory response triggered by Aβ administration. Apocynin additionally instigated adult hippocampal neurogenesis and triggered mitochondrial biogenesis. Conclusions: These primary results strongly advocate apocynin’s nootropic, neurotrophic and neuroprotective potential in an Aβ induced neurotoxicity in rats.

  • Open Access

    Gastrointestinal Dysmotility in the P+L Rat Model of Parkinson’s Disease

    by Dipesh Pokharel, Caroline Swain, Khoi Le, Vaibhavi Peshattiwar, Thyagarajan Subramanian, Kala Venkiteswaran

    Translation: The University of Toledo Journal of Medical Sciences is the online journal launched by the University of Toledo. Manuscripts will be considered on the understanding that they report original work and are not under consideration for publication by any other journal. The journal publishes original articles reporting experimental results of basic or clinical research, case reports, and reviews. The journal uses a single blind peer review system and each manuscript, based on the results presented in its original submission, will be evaluated by two student reviewers and one faculty reviewer. This process will provide an opportunity for medical students, graduate students, residents, fellows and faculty to publish research observation in a timely manner.

  • Open Access

    Targeting the gut to protect from ascending pathology in the paraquat and lectin model of Parkinson's disease

    by Caroline Swain, Vaibhavi Peshattiwar, Khoi Le, Isabel Nester, Kala Venkiteswaran, Thyagarajan Subramanian

    Translation: The University of Toledo Journal of Medical Sciences is the online journal launched by the University of Toledo. Manuscripts will be considered on the understanding that they report original work and are not under consideration for publication by any other journal. The journal publishes original articles reporting experimental results of basic or clinical research, case reports, and reviews. The journal uses a single blind peer review system and each manuscript, based on the results presented in its original submission, will be evaluated by two student reviewers and one faculty reviewer. This process will provide an opportunity for medical students, graduate students, residents, fellows and faculty to publish research observation in a timely manner.


  • Open Access

    Squalamine as a Potential Neuroprotective Agent in Parkinson's Disease Related Cognitive Decline

    by Dipesh Pokharel, Tatiana White, Vaibhavi Peshatiwar, Caroline Swain, Khoi Le, Thyagarajan Subramanian

    Parkinson’s Disease (PD) is a chronic neurodegenerative condition characterized by a range of motor and non-motor clinical manifestations. Motor symptoms such as resting tremor, bradykinesia, rigidity, and postural imbalance, along with non-motor symptoms including cognitive decline, sleep disturbances, constipation, depression, and anxiety, contribute to the multifaceted nature of the disease. Among the various non-motor features under intense investigation is a cognitive decline stand out prominently.In previous research, we introduced a novel rat model of PD by administering subthreshold doses of Paraquat (P) and Lectins (L) orally. This model aimed to simulate the environmental gut-brain pathogenesis of PD, leading to associated nigral synucleinopathy and levodopa-responsive parkinsonism. Notably, protection against PD was observed through subdiaphragmatic vagotomy performed before exposure to P+L (Anselmi L et al., 2018). Studies have suggested the potential protective role of Squalamine, a natural bile salt derived from the dogfish shark, when administered orally (Perni M et al., 2017). Paraquat dichloride is a commonly used herbicide to control weeds and grass, while Lectins are carbohydrate-binding proteins found in uncooked vegetables, dairy, or eggs. Another component is cholecystokinin (CCK), a hormone produced in the small intestine that aids in the digestive process.? Objective: Our hypothesis is that animals with more severe parkinsonian motor symptoms will exhibit poorer performance in various cognitive tasks. Methods: The Y-maze has been used extensively in animal models of PD to assess short-term memory. Twenty-five Sprague Dawley rats were placed in a Y-Maze apparatus with an overhead automated movement tracking system (AnyMaze). For five minutes, each rat’s movement was tracked and scored for their independent spontaneous alternation pattern with minimal distractions. The validity of the software’s output was confirmed by manual scoring. Each spontaneous alternation was reported as a raw score based on the total of triads completed in each trial. We tested this using three treatment groups: no treatment (Normal), paraquat + lectin via oral gavage (P+L), paraquat + lectin and squalamine solution (P+L+S). Within the P+L group, animals exhibited varying degrees of motor deficits as confirmed by our battery of behavioral tests. Results: One-way ANOVA confirmed a significant difference (p=0.02) in spontaneous alternation and a value approaching significance (p=0.090) for the percent spontaneous alternation between treatment groups. Post-hoc analysis using student t-tests shows a significant difference when comparing all three P+L subcategories to normal animals. No significant difference was noted between P+L+S and normal animals. These preliminary results suggest that although motor deficits differed between animals treated with P+L, the short-term memories of these animals were equally affected regardless of the extend of the motor deficits. Conclusion: Parkinsonian symptoms are linked to poorer maze task performance, indicating a motor-cognitive connection. Squalamine treatment improved motor symptoms and boosted maze task performance, suggesting neuroprotection. References: Anselmi, L., Bove, C., Coleman, F. H., Le, K., Subramanian, M. P., Venkiteswaran, K., Subramanian, T., & Travagli, R. A. Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat. NPJ Parkinson's disease, 2018. 4: 30. https://doi.org/10.1038/s41531-018-0066-0 Perni, M., Galvagnion, C., Maltsev, A., Meisl, G., Müller, M. B., Challa, P. K., Kirkegaard, J. B., Flagmeier, P., Cohen, S. I., Cascella, R., Chen, S. W., Limbocker, R., Sormanni, P., Heller, G. T., Aprile, F. A., Cremades, N., Cecchi, C., Chiti, F., Nollen, E. A., Knowles, T. P., … Dobson, C. M. A natural product inhibits the initiation of ?-synuclein aggregation and suppresses its toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2017. 114(6): pp. E1009–E1017. Stoelting Co., IL https://www.any-maze.com/.

  • Open Access

    Evaluation of Daidzein Against Rotenone Induced Parkinson’s Disease and a Potential Involvement of Mitochondrial Biogenesis.

    by Vaibhavi Peshattiwar, Suraj Muke, Aakruti Kaikini, Sneha Bagle, Vikas Dighe, Sadhana Sathaye

    Parkinson’s disease (PD) ranks as second most prevalent neurodegenerative disorder but is devoid of neuroprotective treatment. Approaches with disease modifying ability with symptomatic relief has become an utmost necessity. Further multifactorial nature of PD presents challenges for efficacy evaluation of any potential test compound. The stated study makes an attempt to address these issues by employing a rotenone induced PD model involving a bilateral intranigral stereotactic rotenone injection for evaluation of the neuroprotective efficacy of Daidzein (DZ). DZ a soy isoflavone, is known for its various health benefits viz. immunomodulation, cardiovascular effects etc. In this study, animals after intranigral rotenone (12 μg) injection, were treated with DZ at a dose of 5, 10 and 20 mg/kg for 30 days. The neurobehavioural evaluation comprised of Rota-rod, Open field and Barnes maze test. The biochemical analysis constituting oxidative stress (Reduced glutathione, superoxide dismutase, catalase and lipid peroxidation), inflammation (TNF-α), mitochondrial alteration (complex I activity and biogenesis) was conducted on mid-brain tissue after 30 days of treatment. The SN and striatum was also subjected to immunohistochemical analysis (IHC) for TH positive neurons and Glial Fibrillary Acidic Protein. The analysis revealed significant improvement by daidzein in motor co-ordination and attenuation in cognitive deficits due to rotenone. The biochemical assessment exhibited significant decrement in oxidative stress as well as inflammation. DZ treatment also prevented complex I inhibition and promoted mitochondrial biogenesis eventually contributing to the neuroprotection apparent in IHC. Thus, the results strongly corroborate the neuroprotective potential of DZ against rotenone induced model of PD.